Nkarta击败了2025年Q4收入预期,每股2.29美元,在早期试验中侧重于癌症和自免疫疗法。 Nkarta beat Q4 2025 earnings expectations with $0.29 per share, focusing on cancer and autoimmune therapies in early trials.

Nkarta报告,2025年Q4收入为每股0.29美元,比预期高出0.03美元。 Nkarta reported Q4 2025 earnings of $0.29 per share, beating expectations by $0.03. 临床阶段生物制药公司正在研制针对癌症和自动免疫疾病的NKX019等天然杀手细胞疗法,目前正在第一阶段进行复发/非Hodgkin淋巴瘤和lupus肾炎试验。 The clinical-stage biopharma company, developing natural killer cell therapies like NKX019 for cancer and autoimmune diseases, is in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma and lupus nephritis. 分析员预测的损失从1 2026年的0.34美元减少到4 2026年的0.41美元。 Analysts project losses narrowing from $0.34 in Q1 2026 to $0.41 in Q4 2026. 股票交易额为2.01美元,市场上限为1.4277亿美元,52周范围为1.31至3.40美元,协商一致的“收购”评级为13.25美元。 The stock trades at $2.01 with a $142.77 million market cap, a 52-week range of $1.31 to $3.40, and a consensus "Moderate Buy" rating with a $13.25 target.